This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is a double-blind randomized, parallel group, placebo-controlled dose escalation study (2 cohorts) ofVarespladib Infusion [A-001] for the prevention of acute chest syndrome in patients with sickle cell disease who are at-risk for development of acute chest syndrome (ACS) based on the combination of vaso-occlusive crisis, fever, and elevated serum sPLA2 concentration.
Showing the most recent 10 out of 782 publications